316 related articles for article (PubMed ID: 36706232)
1. Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
Singh RB; Parmar UPS; Ichhpujani P; Jeng BH; Jhanji V
Cornea; 2023 Jun; 42(6):731-738. PubMed ID: 36706232
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-Associated Uveitis after COVID-19 Vaccination: Vaccine Adverse Event Reporting System Database Analysis.
Singh RB; Parmar UPS; Kahale F; Agarwal A; Tsui E
Ophthalmology; 2023 Feb; 130(2):179-186. PubMed ID: 36055601
[TBL] [Abstract][Full Text] [Related]
3. Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States.
Abara WE; Gee J; Marquez P; Woo J; Myers TR; DeSantis A; Baumblatt JAG; Woo EJ; Thompson D; Nair N; Su JR; Shimabukuro TT; Shay DK
JAMA Netw Open; 2023 Feb; 6(2):e2253845. PubMed ID: 36723942
[TBL] [Abstract][Full Text] [Related]
4. Retinal vascular occlusion following SARS-CoV-2 vaccination: A VAERS database analysis.
Singh RB; Parmar UPS; Gupta R; Vega Garcia AJ; Cho W; Singh KP; Agarwal A
Ophthalmol Sci; 2023 Jun; 4(1):100354. PubMed ID: 37362418
[TBL] [Abstract][Full Text] [Related]
5. Risk of Herpes Zoster Ophthalmicus After COVID-19 Vaccination in a Large US Health Care Claims Database.
Akpandak I; Sechrist SJ; Claire Miller D; Sun Y; Arnold BF; Daniel Kelly J; Acharya NR
Am J Ophthalmol; 2024 Feb; 258():139-144. PubMed ID: 37423396
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Severe COVID-19 Illness Following Vaccination and Booster With BNT162b2, mRNA-1273, and Ad26.COV2.S Vaccines.
Kelly JD; Leonard S; Hoggatt KJ; Boscardin WJ; Lum EN; Moss-Vazquez TA; Andino R; Wong JK; Byers A; Bravata DM; Tien PC; Keyhani S
JAMA; 2022 Oct; 328(14):1427-1437. PubMed ID: 36156706
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vector-Based Ad26.COV2.S Vaccine for the Prevention of COVID-19 among Dialysis Patients.
Brunelli SM; Sibbel S; Karpinski S; Marlowe G; Walker AG; Giullian J; Van Wyck D; Kelley T; Lazar R; Zywno ML; Connaire JJ; Young A; Tentori F
J Am Soc Nephrol; 2022 Apr; 33(4):688-697. PubMed ID: 35135894
[TBL] [Abstract][Full Text] [Related]
8. Incidence of multiple sclerosis relapses and pseudo-relapses following COVID-19 vaccination.
Labani A; Chou S; Kaviani K; Ropero B; Russman K; Becker D
Mult Scler Relat Disord; 2023 Sep; 77():104865. PubMed ID: 37418929
[TBL] [Abstract][Full Text] [Related]
9. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
10. [Herpes Zoster Ophthalmicus after Pfizer BNT162b2 and Moderna mRNA-1273 vaccination in two young and immunocompetent patients].
Amblard MA; Costantini E; Hayek G; Ricaud X
J Fr Ophtalmol; 2022 Nov; 45(9):1000-1003. PubMed ID: 36155145
[TBL] [Abstract][Full Text] [Related]
11. Herpetic Eye Disease Following the SARS-CoV-2 Vaccinations.
Cohen S; Olshaker H; Fischer N; Vishnevskia-Dai V; Hagin D; Rosenblatt A; Zur D; Habot-Wilner Z
Ocul Immunol Inflamm; 2023 Aug; 31(6):1151-1162. PubMed ID: 35914308
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine.
Akpandak I; Miller DC; Sun Y; Arnold BF; Kelly JD; Acharya NR
JAMA Netw Open; 2022 Nov; 5(11):e2242240. PubMed ID: 36383382
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
Cerqueira-Silva T; Andrews JR; Boaventura VS; Ranzani OT; de Araújo Oliveira V; Paixão ES; Júnior JB; Machado TM; Hitchings MDT; Dorion M; Lind ML; Penna GO; Cummings DAT; Dean NE; Werneck GL; Pearce N; Barreto ML; Ko AI; Croda J; Barral-Netto M
Lancet Infect Dis; 2022 Jun; 22(6):791-801. PubMed ID: 35366959
[TBL] [Abstract][Full Text] [Related]
14. Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study.
Bohnert AS; Kumbier K; Rowneki M; Gupta A; Bajema K; Hynes DM; Viglianti E; O'Hare AM; Osborne T; Boyko EJ; Young-Xu Y; Iwashyna TJ; Maciejewski M; Schildhouse R; Dimcheff D; Ioannou GN
BMJ; 2023 May; 381():e074521. PubMed ID: 37220941
[TBL] [Abstract][Full Text] [Related]
15. Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on.
Mangat HS; Musah A; Luedtke S; Syed AA; Maramattom BV; Maruthanal J; Bosman A; Kostkova P
Front Public Health; 2022; 10():972464. PubMed ID: 36311588
[TBL] [Abstract][Full Text] [Related]
16. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink.
Hanson KE; Goddard K; Lewis N; Fireman B; Myers TR; Bakshi N; Weintraub E; Donahue JG; Nelson JC; Xu S; Glanz JM; Williams JTB; Alpern JD; Klein NP
JAMA Netw Open; 2022 Apr; 5(4):e228879. PubMed ID: 35471572
[TBL] [Abstract][Full Text] [Related]
17. Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers.
Brunner WM; Freilich D; Victory J; Krupa N; Scribani MB; Jenkins P; Lasher EG; Fink A; Shah A; Cross P; Bush V; Peek LJ; Pestano GA; Gadomski AM
Int J Infect Dis; 2022 Oct; 123():183-191. PubMed ID: 36044963
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant.
Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L
Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006
[TBL] [Abstract][Full Text] [Related]
19. Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis.
Singh RB; Li J; Parmar UPS; Jeng BH; Jhanji V
Br J Ophthalmol; 2023 Dec; 108(1):17-22. PubMed ID: 36575625
[TBL] [Abstract][Full Text] [Related]
20. Myocarditis and pericarditis in individuals exposed to the Ad26.COV2.S, BNT162b2 mRNA, or mRNA-1273 SARS-CoV-2 vaccines.
Pareek M; Sessa P; Polverino P; Sessa F; Kragholm KH; Sessa M
Front Cardiovasc Med; 2023; 10():1210007. PubMed ID: 38075965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
